Targeting Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors (MPNST) in a Phase II Study of Everolimus in Combination with Bevacizumab (SARC016).

Brigitte C WidemannYao LuDenise ReinkeScott H OkunoChristian F MeyerGregory M CoteRashmi Chugh Mohammed M Milhem Angela C Hirbe Ae Rang KimBrian TurpinJoseph G PresseyEva DombiNalini JayaprakashLee J HelmanNdidi OnwudiweKaren CichowskiJohn P Perentesis

Published in: Sarcoma (2019)

With a CBR of 12% (3/25), the combination of everolimus and bevacizumab did not reach the study's target response rate and is not considered active in refractory MPNST.

Keyphrases

phase ii study
peripheral nerve
open label
metastatic colorectal cancer
signaling pathway
locally advanced
late onset
oxidative stress
squamous cell carcinoma
pi k akt
randomized controlled trial
radiation therapy
early onset
nuclear factor
rectal cancer
drug induced